Non-shockable niche Target hospitals and EMS providers dealing with non-shockable cardiac arrest, where the NEURESCUE device is positioned as the first approved solution to restore or bridge to recovery, addressing a critical unmet need with high potential impact.

Clinical impact Emphasize potential to increase survival rates for non-shockable cases by rapidly improving blood flow to heart and brain, offering a differentiator in emergency response portfolios and aligning with patient outcome priorities.

Strategic partnerships Leverage connections with hospitals, trauma centers, and cardiovascular programs; pursue collaborations with heart-lung machine and PCI service lines to position NEURESCUE as a bridging technology in advanced resuscitation pathways.

Early-stage traction Highlight Series A funding and board-level expertise to reassure investors and procurement teams; target expansion opportunities in Denmark and other regions with supportive regulatory environments for medical devices.

Sales readiness Develop use-case focused collateral and clinician-friendly demonstrations that explain fluoroscopy-free balloon occlusion benefits, automated inflation, and sensor feedback to drive emergency department, OR, and catheter lab adoption.